MedWatch

Eli Lilly and Almirall report promising results from phase III atopic eczema study

A collaboration between Spanish firm Almirall and US-based Eli Lilly has so far resulted in positive results from three of five global phase III studies with the drug lebrikizumab. Marketing rights for Europe and the rest of the world have been split between the firms.

Photo: Mikkel Aabenhus Hemmingsen / MedWatch

Pharmaceutical giant Eli Lilly and Spanish dermatology company Almirall have come together to develop a treatment for atopic dermatitis, also known as atopic eczema.

The partnership is now ready to publicize more partial results from a global phase III program, this time demonstrating significant improvements in disease severity, a joint press release reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs